This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Opdivo
  • /
  • Study of BMS-936558 vs. Dacarbazine in Untreated, ...
Clinical trial

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma (CheckMate 066)

Read time: 1 mins
Last updated:1st Jan 2013

The purpose of this study is to compare the clinical benefit, as measured by duration of overall survival, of BMS-936558 vs. Dacarbazine in subjects with previously untreated, unresectable or metastatic melanoma


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Estimated Enrollment: 410
Study Start Date: January 2013
Estimated Study Completion Date: November 2016
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Arm A: BMS-936558(Nivolumab) with Placebo matching Dacarbazine
- Active Comparator: Arm B: Dacarbazine with Placebo matching BMS-936558(Nivolumab)



Category Value
Study start date 2013-01-01

View full details